- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 03.12. | Philips, Mayo Clinic team up on AI for cardiac MRI scans | ||
| 03.12. | Maze Therapeutics looks to steer lead kidney disease assets through the clinic with $115M series D | ||
| 03.12. | Siemens Healthineers debuts automated AI for abdomen ultrasound exams | ||
| 03.12. | Janux's T-cell engager makes waves, again, with 'best-in-class' data drop: analyst | ||
| 03.12. | Gilead taps German biotech Tubulis for solid tumor ADC development deal worth up to $465M | ||
| 03.12. | Bristol Myers Squibb taps AI Proteins in drug discovery collaboration worth up to $400M | ||
| 03.12. | Roivant spinout ends development of lung disease asset after phase 2 fail | ||
| 03.12. | Cour links up with Roche's Genentech in autoimmune deal that could exceed $940M | ||
| 03.12. | Takeda pays Keros $200M upfront for rival to BMS' booming blockbuster Reblozyl | ||
| 03.12. | Ipsen enlists MAITs to take down solid tumors, betting $610M on Biomunex's novel T-cell engagers | ||
| 02.12. | GE HealthCare to take over Japanese radiopharmaceutical venture | ||
| 02.12. | Merus' head and neck cancer candidate bolsters 'best-in-disease' profile with new data drop: analyst | ||
| 02.12. | Novocure's tumor treating electric fields clear phase 3 pancreatic cancer trial | ||
| 02.12. | Alligator Bioscience clamps down on costs with plans to lay off 70% of workforce to stay afloat | ||
| 02.12. | Novartis pays PTC $1B upfront for midphase Huntington's program, reestablishing itself in R&D race | ||
| 02.12. | FDA rejects Applied filing for rare disease approval on clinical grounds, sinking stock | ||
| 27.11. | Trump picks Jay Bhattacharya, Stanford economist and pandemic policy critic, as NIH director | ||
| 27.11. | Kronos to lay off 83% of workforce, change CEOs after mothballing lone clinical asset | ||
| 27.11. | Outlook's stock plummets after eye drug fails to match Lucentis, but biotech still plans FDA filing | ||
| 27.11. | PTC sells priority review voucher from Kebilidi approval for $150M | ||
| 27.11. | EQBMED launches trial sites tool to assess performance and boost diversity | ||
| 27.11. | PTC axes utreloxastat program after phase 2 ALS failure | ||
| 27.11. | Idorsia teases Tryvio global licensing deal while planning to lay off 270 staff | ||
| 26.11. | Acadia nabs rights to Saniona's tremor asset in $582M biobucks deal | ||
| 26.11. | Embecta to shutter newly-cleared insulin patch pump program amid restructuring |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
